ArticleACS omega2024
Incremental Inverse Design of Desired Soybean Phenotypes.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present an application of computational inverse design, which reverses the conventional trial-and-error forward design paradigm, optimizes biological phenotype by directly modifying genotype. The limitations of inverse design in genotype-to-bulk phenotype (G-BP) mapping can be addressed via an established design paradigm: "design, build, test, learn" (DBTL), where computational inverse design automates both the design and learn phases. In any context, inverse design is limited by the fundamental "one-to-many" nature of the inverse function. G-BP inverse design is further limited by the number of single nucleotide polymorphisms that can be made to a member of the population while maintaining feasibility of genotype creation and biological viability. Considering these limitations, we propose a design paradigm based on incremental optimization of phenotype through a combined computational and experimental approach. We intend this work to be a foundational synthesis of well-known techniques applied to the context of genotype-to-bulk phenotype inverse design, which has not yet been performed in the literature. The design pipeline can optimize phenotype by either directly proposing genotypic changes, or simply by suggesting parents to be used for selective breeding. The soybean nested association matrix data set is used to present an in silico case study of the design pipeline by performing optimization that maximizes protein content while constraining other phenotypes. A random forest (RF) is used to model the genotype-to-phenotype relationship, and a genetic algorithm is used to query the RF until a feasible genotype with desired phenotype is discovered. After 20 in silico DBTL cycles, a final population of individuals with a mean protein content of 36.13%, an increase of three standard deviations above the original mean is suggested.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.